This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
by Zacks Equity Research
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
NVSNegative Net Change BMYNegative Net Change RPRXNegative Net Change CYTKNegative Net Change
biotechs medical pharmaceuticals
Regeneron (REGN) Announces Positive Data on Oncology Candidate
by Zacks Equity Research
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
REGNNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.
FOLDNegative Net Change
biotechs medical
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
by Zacks Equity Research
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
DCPHPositive Net Change ENTXPositive Net Change ANVSNo Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
by Zacks Equity Research
Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.
GSKNegative Net Change BIIBNegative Net Change PTCTNegative Net Change IONSNegative Net Change LRMRNegative Net Change
biotechs pharmaceuticals
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
by Zacks Equity Research
The FDA bestows RMAT designation to Cartesian's (RNAC) lead pipeline candidate, Descartes-08, for treating myasthenia gravis. Shares rise.
NERVPositive Net Change MRNSPositive Net Change KRYSNegative Net Change RNACNegative Net Change
biotechs
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
by Zacks Equity Research
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
PFENegative Net Change HRTXNo Net Change MRNSPositive Net Change ARQTPositive Net Change
biotechs medical pharmaceuticals vaccines
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
by Zacks Equity Research
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
KRYSNegative Net Change ANVSNo Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
by Zacks Equity Research
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
NVSNegative Net Change BIIBNegative Net Change ATRAPositive Net Change MORPositive Net Change
biotechs
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
by Zacks Equity Research
Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs immuno-therapy medical pharmaceuticals
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
by Zacks Equity Research
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
BMYNegative Net Change LGNDPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
by Zacks Equity Research
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
RDYNegative Net Change ANVSNo Net Change ALXONegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
by Zacks Equity Research
GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
GSKNegative Net Change TEVANegative Net Change ATRAPositive Net Change ENTXPositive Net Change
biotechs
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
by Zacks Equity Research
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
DYNPositive Net Change LGNDPositive Net Change SRPTNegative Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
LGNDPositive Net Change PTCTNegative Net Change ANIPNegative Net Change ANVSNo Net Change
biotechnology biotechs medical pharmaceuticals
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
by Zacks Equity Research
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
VRTXNegative Net Change LGNDPositive Net Change CRSPPositive Net Change
biotechs
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
by Zacks Equity Research
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
TEVANegative Net Change EXELNegative Net Change LGNDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
by Zacks Equity Research
Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.
SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs messenger-rna pharmaceuticals vaccines
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
by Zacks Equity Research
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
LGNDPositive Net Change ANIPNegative Net Change BGNEPositive Net Change ANVSNo Net Change
biotechnology biotechs medical oncology-screening precious-metals
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
by Zacks Equity Research
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
Gilead (GILD) Announces Positive Interim Results on PBC Drug
by Zacks Equity Research
Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
GILDNegative Net Change LGNDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
PBYINegative Net Change
biotechs medical
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
by Zacks Equity Research
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
INCYPositive Net Change LGNDPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
LLYNegative Net Change LGNDPositive Net Change ANIPNegative Net Change ANVSNo Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
by Zacks Equity Research
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
AMGNNegative Net Change LGNDPositive Net Change ANIPNegative Net Change ANVSNo Net Change
biotechs